The American Journal of Human Genetics, Volume 111

**Supplemental information** 

Adaptation of a mutual exclusivity framework

to identify driver mutations

within oncogenic pathways

Xinjun Wang, Caroline Kostrzewa, Allison Reiner, Ronglai Shen, and Colin Begg




Figure S1: Illustration of the Observed Binary Mutation Status, Estimated Posterior Probability of Driver Mutation, and the Distribution of Binary Tumor Mutational Burden (TMB) for the RTK-RAS Pathway from the InterMEL Study. All 38 genes are included.




Figure S2. Illustration of the Observed Binary Mutation Status, Estimated Posterior Probability of Driver Mutation, and the Distribution of Binary Tumor Mutational Burden (TMB) for the PI3K Pathway from TCGA-UCEC Data.

SKCM	BRCA	LGG	LUAD	HNSC	THCA	PRAD	LUSC	BLCA	KIRC	UCEC
Anone An				A Construction of the second s	Provide a second	Autors Autors			And a second sec	Annu Carlon and Annu Carlon an
SKCM	BRCA PIKSCA		LUAD	HNSC PIK3CA	THCA Pikaca	PRAD	LUSC	BLCA Pik3C4	KIRC	
Much Anarea Property	Norminal Antice State St			And the second s	And the second s	Mood And And And And And And And And And An		PTCN PTSCI P	ATT2 PPGAC P	
SKCM	BRCA	LGG		HNSC				BLCA	KIRC	UCEC
Anone A	mmp	Ace A	Another A	Constant of the second se	Control of the second sec	Che Ch Che Ch	Ann A		(1) (1) (2) (	Constant of the second se

Figure S3. Driver Gene Nomination by Different Methods for All Eleven Cancer Sites. A: RTK-RAS pathway; B: PI3K pathway; C: Wnt pathway. TCGA disease codes and abbreviations: BRCA, breast cancer; LGG, lower grade glioma; UCEC, uterine corpus endometrial carcinoma; LUAD, lung adenocarcinoma; HNSC, head and neck squamous cell carcinoma; THCA, papillary thyroid carcinoma; PRAD: Prostate adenocarcinoma; LUSC, lung squamous cell carcinoma; BLCA, urothelial bladder cancer; SKCM, cutaneous melanoma; KIRC: clear cell kidney carcinoma.